Poređenje analgetske efikasnosti blokova nerava pod kontrolom ultrazvuka pomoću tri anestetika različite dužine dejstva u lečenju rezistentnog neuropatskog bola donjih ekstremiteta

  • Olivera Jovanikic Neurosurgeon
  • Gordana Andjelić Military Medical Academy, Medical Research Institute, Belgrade, Serbia
  • Milan Lepić Military Medical Academy, Neurosurgery Clinic, Belgrade, Serbia;
  • Dušica Mirković University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia
  • Bojan Jovanović Military Medical Academy, Neurology Clinic, Belgrade, Serbia
  • Tamara Dragović Military Medical Academy, Endocrinology Clinic, Belgrade, Serbia
  • Goran Pavličević Military Medical Academy, Neurosurgery Clinic, Belgrade, Serbia
  • Toplica Lepić Military Medical Academy, Neurology Clinic, Belgrade, Serbia
Ključne reči: neuralgia, nerve block, ultrasonography, lower extremity

Sažetak


Abstract

 

Background/Aim. The neuropathic pain (NP) treatment is a big medical and socioeconomical problem. The new sorts of the NP treatment was developed and are applied in case of a medical treatment failure. The aim of this work was to investigate the efficacy of the ultrasound-assisted treatment of the resistant and chronic peripheral neuropathic pain with the local anesthetic nerve blocks. Due to the inefficacy of conventional treatment, three local anesthetics (short-acting, medium-term and long-acting) were administered in a series of the same minimal dose on a daily basis. Complications, side effects, the execution time of procedure and the onset time of local anesthetic were also investigated. Methods. In this prospective, randomized and double-blinded study, 108 patients (of which 53 were diagnosed with diabetes and 55 with radiculopathy) with the resistant and chronic peripheral neuropathic pain in the lower extremities were treated with a series of ultra-sound assisted peripheral nerve blocks. The conventional treatment was exhausted. The presence of this neuropathic pain was confirmed by, at least, one of the three scales – the Leeds Assesment of Neuropathic Simptoms and Signs (LANSS) scale, the Dolour Neuropathic 4 questions (DN4) scale and the pain DETECT(PD-Q) scale. Other therapies were not applied. The nerve blocks were administered on a daily basis until the relief of pain (visual analogue scale – VAS < 30), and after that, two additional nerve blocks were given. The three local anesthetics of the different duration of therapeutic effect were given at the same minimal dose: the schort-acting (1% procaine-chloride solution), medium-term (1% lidocaine-chloride solution) and long-acting (0.25% levobupivacaine-chloride solution) local anesthetics were used. The therapeutic efficacy was measured with the percentage reduction in the pain intensity on the VAS scale before and after the therapy and one month after the treatment: > 50% – excellent results; 31–49% – good results; < 30% the therapy did not work. The side effects, complications, the execution duration of procedure, the onset time of numbness, the number of corrections of the needle direction were recorded as well. Results. For all three groups: nerve blocks took 5.4 ± 1.48 minutes to do (withouth difference among the groups), the onset of numbness occured, on average, within 3.75 ± 2.62 minutes (withouth differences among the groups), and the need for corrections of needle direction was minimal (1.03 ± 0.17 corrections). All the patients experienced a loss of pain sensation (VAS < 30); when a long-acting anesthetic was used, the number of required nerve blocks was significant (p < 0.001) smallest (4.33 ± 0.63 blocks), than in other two groups, and the percentage pain reduction was highest (73.13%) (p < 0.001). The pain relief lasted one month after the therapy without the application of any other therapy. Neither complications nor side effects were observed. Conclusion. The procedure dercibed is a safe, efficient and easy-to-perform and does not lead to any complications and side effects. The pain relief is achieved most effectively and rapidly with the long-acting local anesthetics, and maintained even for one month without the introduction of any additional therapy.

Biografija autora

Olivera Jovanikic, Neurosurgeon
Neurosurgery Clinic

Reference

REFERENCES

Merskey H, Bogduk N. Classification of Cronic Pain. 3rd ed. Seattle (WA): IASP Press; 2002.

Treede R, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, et al. A classification of chronic pain for ICD-11. Pain 2015; 156(6): 1003–7.

Ludwig J, Baron R. Neuropathischer Schmerz. MMW Fortschr Med 2005; 147(49–50): 76–8.

McDermott AM, Toelle TR, Rowbotham DJ, Schaefer CP, Dukes EM. The burden of neuropathic pain: Results from a cross-sectional survey. Eur J Pain 2006; 10(2): 127–35.

Moulin DE, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, et al. Pharmacological management of chronic neuropathic pain: Revised consensus statement from the Canadian Pain Society. Pain Res Manag 2014; 19(6): 328–35.

Kopf A, Patel NB. Management in neuropathic pain. In: Kopf A, Patel NB, editor. Guide to Pain Management in Low-Resource Settings. Berlin: IASP® • SEATTLE; 2010.

Dobson JL, McMillan J, Li L. Benefits of exercise intervention in reducing neuropathic pain. Front Cell Neurosci 2014; 8: 102.

Deranovic DV, Hrabac P, Skegro D, Smiljanic R, Dobrota S, Prkacin I, et al. The impact of neuropathic pain and other comorbidities on quality of life in patients with diabetes. Health Qual Life Outcomes 2014; 12: 171.

Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005; 114(1–2): 29–36.

Bouhassira D, Attal N, Fermanian J, Alchaar H, Gautron M, Mas-quelier E, et al. Development and validation of the Neuro-pathic Pain Symptom Inventory. Pain 2004; 108(3): 248–57.

Benzon HT. The neuropathic pain scales. Reg Anesth Pain Med 2005; 30(5): 417–21.

Bennett M. The LANSS Pain Scale: The Leeds assessment of neuropathic symptoms and signs. Pain 2001; 92(1–2): 147–57.

Yamamoto H, Sakura S, Wada M, Shido A. A prospective, ran-domized comparison between single- and multiple-injection techniques for ultrasound-guided subgluteal sciatic nerve block. Anesth Analg 2014; 119(6): 1442–8.

Freynhagen R, Baron R, Gockel U, Tölle TR. painDETECT: A new screening questionnaire to identify neuropathic compo-nents in patients with back pain. Curr Med Res Opin 2006; 22(10): 1911–20.

Baron R. Diagnosis and Treatment of Neuropathic Pain. Dtsch Arztebl 2006; 103(41): A2720–30.

Park CH, Jung SH, Han CG. Effect of intravenous lidocaine on the neuropathic pain of failed back surgery syndrome. Korean J Pain 2012; 25(2): 94–8.

Braune S. Evidenzbasierte Pharmakotherapie neuropathischer Schmerzsyndrome. MMW Fortschr Med 2004; 146(50): 49–51.

Baron R, Binder A. How neuropathic is sciatica? The mixed pain concept. Orthopade 2004; 33(5): 568–75. (German)

de la Calle JL, De Andres J, Pérez M, López V. Add-on treatment with pregabalin for patients with uncontrolled neuropathic pain who have been referred to pain clinics. Clin Drug Investig 2014; 34(12): 833–44.

Dzung H, de Leon-Casasola OA. Neuropathic pain. In: Sinatra RS, Jahr JS, Watkins-Pitchford JM, editors. The Essence of Analgesia and Analgesics. New York: Cambridge University Press;. 2011. p. 30–7.

Dworkin RH, O'Connor AB, Kent J, Mackey SC, Raja SN, Stacey BR, et al. Interventional management of neuropathic pain: NeuPSIG recommendations. Pain 2013; 154(11): 2249–61.

Carroll IR, Younger JW, Mackey SC. Pain quality predicts lido-caine analgesia among patients with suspected neuropathic pain. Pain Med 2010; 11(4): 617–21.

Brod M, Blum SI, Bushnell DM, Ramasamy A. Development and validation of the Diabetic Peripheral Neuropathic Pain Impact (DPNPI) measure, a patient-reported outcome measure. Qual Life Res 2015; 24(12): 3001–14.

Likar R, Demschar S, Kager I, Neuwrsch S, Pipam W, Sittl R. Treatment of localized neuropathic pain of different etiologies with the 5% lidocain medicated plaster: A case series. Intern J Gen Med 2015; 8: 9–14.

Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, et al. European Federation of Neurological Societies(EFNS) guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010; 17(9): 1113–e88.

Webster`s New World Medical Dictionary. 3rd ed. Boston: Houghton Mifflin Harcourt; 2009. p. 275.

Stewart EA. Uterine fibroids and evidence-based medicine-not an oxymoron. N Engl J Med 2012; 366(5): 471–3.

Golzari SE, Soleimanpour H, Mahmoodpoor A, Safari S, Ala A. Lidocaine and Pain Management in the Emergency Department. A Review Article. Anesth Pain Med 2014; 4(1): e15444.

Onysko M, Legerski P, Potthoff J, Erlandson M. Targeting neuro-pathic pain: Consider these alternatives. J Fam Pract 2015; 64(8): 470–5.

Ray AI, Rhonwyn U, Francis MC. Pain as a Perceptual Experi-ence. In: Deer TD, editor. Treatment of Chronic Pain by Interventional Approaches. New York: Heidelberg Dordrecht; 2015. p. 1–15.

Caroll IR, Younger JW, Mackey SC. Pain quality predicts lido-caine analgesia amnog patients with suspected neuropathic pain. Pain Med 2010; 11(4): 617–21.

Jankovic D. Use of Local Anesthetics in Regional Anesthesia and Pain Therapy. In: Jankovic D, Peng PW, editors. Regional Nerve Blocks in Anesthesia and PainTherapy. Switzerland, Geneva: Springer International Publishing; 2015. p. 2–16.

Jankovic D. Regional nerve blocks and Infiltration therapy in clinical practice. In: Jankovic D, Peng PW editors. Regional Nerve Blocks in Anesthesia and PainTherapy. Switzerland, Gemeva: Springer International Publishing; 2015. p. 17–25.

Likar R, Kager I, Obmann M, Pipam W, Sittl R. Treatment of localized neuropathic pain after disc herniation with 5% lido-caine mediated plaster. Int J Gen Med 2012; 5: 689–92.

Müller-Schwefe GH. European survey of chronic pain patients: results for Germany. Curr Med Res Opin 2011; 27(11): 2099–106.

Sabatowski R, Hans G, Tacken I, Kapanadze S, Buchheister B, Baron R. Safety and efficacy outcomes of long-term treatment up to 4 years with 5% lidocaine medicated plaster in patients with post-herpetic neuralgia. Curr Med Res Opin 2012; 28(8): 1337–46.

Basit A, Basit KA, Fawwad A, Shaheen F, Fatima N, Petropoulos IN, et al. Vitamin D for the treatment of painful diabetic neu-ropathy. BMJ Open Diabetes Res Care 2016; 4(1): e000148.

Cao X, Zhao X, Xu J, Liu Z, Li Q. Ultrasound-guided technol-ogy versus neurostimulation for sciatic nerver block: A meta-analysis. Int J Clin Exp Med 2015; 8(1): 273–80.

Cohen K, Shinkazh N, Frank J, Israel I, Fellner C. Pharmacologi-cal treatment of diabetic peripheral neuropathy. P T. 2015; 40(6): 372–88.

Objavljeno
2021/02/10
Rubrika
Originalni članak